Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. | After Novartis and Roche grew their sales last year, the ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

CeriBell's AI-powered EEG system offers rapid seizure diagnosis. The stock is undervalued by at least 50% over the long-term, ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Novartis has a collaboration agreement with ... With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains.

Fox sold out of its inventory of in-game spots by early November, with a 30-second commercial reportedly going for $7 million, according to Adweek. The showdown takes place Feb. 9.

Novartis (NVS) reported $13.15 billion in revenue ... With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains.

Since 2021, there’s been an increase in representation of people from underrepresented and underserved communities in Super ...

The Super Bowl has always been more than a game—it’s a cultural barometer, reflecting how brands engage with audiences at the ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...